Should You Add Pluristem Therapeutics Inc. (PSTI) Stock to Your Portfolio?

Thursday, April 16, 2020 11:32 AM | InvestorsObserver Analysts

Pluristem Therapeutics Inc. (PSTI) stock is higher by 75.09% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary ranking system, gives PSTI stock a score of 79 out of a possible 100.

That rank is primarily influenced by a short-term technical score of 100. PSTI's rank also includes a long-term technical score of 100. The fundamental score for PSTI is 38. In addition to the average rating from Wall Street analysts, PSTI stock has a mean target price of 15.125. This means analysts expect the stock to climb 51.55% over the next 12 months.

Overall Score - 79
PSTI has an Overall Score of 79. Find out what this means to you and get the rest of the rankings on PSTI!

What's Happening with PSTI Stock Today

Pluristem Therapeutics Inc. (PSTI) stock is higher by 1.38% while the S&P 500 is higher by 0.43% as of 11:30 AM on Thursday, Apr 16. PSTI is higher by $0.14 from the previous closing price of $9.84 on volume of 3,135,382 shares. Over the past year the S&P 500 has fallen -3.62% while PSTI is higher by 75.09%. PSTI lost -$8.02 per share in the over the last 12 months.

Click Here to get the full Stock Score Report on Pluristem Therapeutics Inc. (PSTI) Stock.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 65% with annual

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

You May Also Like

Related Articles

Sector Update: Afternoon Recovery for Health Care Stocks

Sector Update: Health Care

Where Will Celldex Therapeutics, Inc. (CLDX) Stock Go Next After It Is Up 23.13% in a Week?

Seelos Therapeutics Inc (SEEL) Stock: What Does the Chart Say?

Related Companies